Previous studies [10–12] showed that advanced-stage ovarian cancer patients with BRCA1/2 mutations tend to have higher response rates to platinum-based chemotherapy, longer PFS, and a higher benefit from NAC. Here, BRCA1 is linked to ovarian carcinoma.